Compounded vs. Brand-Name GLP-1: What Your Prescription Actually Means

The most important decision in your GLP-1 prescription isn’t which medication — it’s which version. Brand-name and compounded GLP-1 medications use the same active ingredients, but the similarities largely end there. Understanding the differences helps you make an informed choice.

Brand-Name: What You Get

Brand-name medications (Wegovy, Ozempic, Zepbound, Mounjaro) are manufactured by Novo Nordisk or Eli Lilly in FDA-inspected facilities under Current Good Manufacturing Practice (cGMP) standards. Every batch is tested for potency, purity, sterility, and stability. The medications come in pre-filled injection pens with precise dosing mechanisms. They carry FDA approval based on large clinical trials involving tens of thousands of participants.

Compounded: What You Get

Compounded versions are prepared by licensed pharmacies using pharmaceutical-grade semaglutide or tirzepatide. Two types of pharmacies compound these medications:

• 503A pharmacies compound individual prescriptions for specific patients. They’re regulated by state pharmacy boards and the FDA. They fill prescriptions one at a time based on physician orders.
• 503B outsourcing facilities can compound in larger batches without individual prescriptions. They’re registered with the FDA and subject to more frequent inspections, closer to traditional pharmaceutical manufacturing oversight.

Compounded medications typically come in multi-dose vials requiring you to draw doses with an insulin syringe, though some providers now offer pre-filled syringes, sublingual tablets, or even oral formulations.

The Quality Question

This is where the conversation gets nuanced. Brand-name medications have the deepest quality assurance — every step from raw material sourcing to final packaging is FDA-supervised. Compounded medications rely on state pharmacy board oversight, which varies in rigor by state. The vast majority of licensed compounding pharmacies produce safe, effective medications. But quality incidents have occurred — contamination, potency inconsistencies, sterility failures — primarily at pharmacies operating outside their licensing scope or under inadequate oversight.

The Pricing Gap

Brand-name: $800–$1,350/month at list price (before insurance or savings programs). Compounded: $149–$399/month. This 3–5x price difference is the primary driver of compounded GLP-1 adoption. For patients without insurance coverage, the compounded path may be the only financially viable option.

How to Choose

• Choose brand-name if: You have insurance coverage, you want maximum regulatory assurance, you prefer the convenience of pre-filled pens, or you’re uncomfortable with compounding pharmacy variability.
• Choose compounded if: You’re paying out of pocket, you’ve verified your provider’s pharmacy credentials, and you’re comfortable with vial-and-syringe administration. Ask your provider which pharmacy they use, verify its state license, and confirm whether it’s a 503A or 503B facility.